"Keillor TG2 Inhibitors" (acrylamide compounds)

Compounds AA9 (Z015), NC9 (Z016) and VA4 (Z017), were developed and produced by Dr. Jeffrey Keillor, Department of Chemistry and Biomolecular Sciences, University of Ottawa, Canada. The mechanism-based blockers carry an irreversible acting acrylamide warhead linked to a lysine side chain. Especially the NC9 and VA4 compounds are valuable tools shown to lock TG2 in the open conformation in vitro and in living cells, and to abolish GTP binding. Further, the molecules halt the proliferation and invasion of cancer stem cells. Find more details in the respective PDS.

The “Keillor TG2 Inhibitors” bear an acrylamide warhead, being attacked by the active site cysteine residue (1) to form an irreversible complex (2,3).

Art. No.
Z015 Keillor inhibitor AA9
10 mg
400 €
Z016 Keillor inhibitor NC9
10 mg
400 €
Z017 Keillor inhibitor VA4
10 mg
400 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • Canceled: Gordon Research Conference - Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy